MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Organogenesis Holdings Operating Income 2011-2026 | ORGO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.28 M | 12.5 M | 22.3 M | 72.2 M | 26.7 M | -29.9 M | -51.6 M | -5.49 M | -8.78 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.2 M | -51.6 M | 4.09 M |
Quarterly Operating Income Organogenesis Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.7 M | -12.6 M | -26.7 M | - | 6.24 M | -13.9 M | -3.85 M | - | 8.05 M | 9.74 M | -4 M | - | 1.78 M | 11.9 M | -128 K | - | 16.3 M | 23.6 M | 12.6 M | - | 22.8 M | -2.25 M | -15.1 M | - | -8.26 M | -7.32 M | -12.1 M | -4.48 M | -10.1 M | -17 M | -20 M | -2.4 M | -2.62 M | 2.5 M | -2.97 M | -1.3 M | -14.5 K | -500 | -15.6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.6 M | -26.7 M | -935 K |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.06 | - | $ 114 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.13 | - | $ 266 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
30.5 M | $ 38.6 | - | $ 1.42 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.55 | - | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.58 | -5.37 % | $ 64.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | - | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.92 | - | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 11.9 | 1.06 % | $ 845 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.9 | -0.12 % | $ 21 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.73 | - | $ 2.09 B | Canada |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.53 | - | $ 3.37 M | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.37 | -3.52 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 11.39 | - | $ 1.58 B | USA |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.22 | -0.89 % | $ 23.2 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 22.1 | - | $ 1.02 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.52 | - | $ 340 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.89 | - | $ 17.9 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.67 | -3.51 % | $ 141 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.77 | -1.93 % | $ 3.32 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.75 | 0.33 % | $ 35.9 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.96 | - | $ 243 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.75 | - | $ 3.41 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 7.36 | - | $ 4.55 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |